-- Positive data from 876-patient head-to-head trial versus Shingrix ® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, ...
Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback